The AEBP2 antibody targets the Adipocyte Enhancer-Binding Protein 2 (AEBP2), a zinc finger-containing transcriptional repressor involved in epigenetic regulation. AEBP2 functions as a regulatory subunit of the Polycomb Repressive Complex 2 (PRC2), which mediates histone H3 lysine 27 trimethylation (H3K27me3), a chromatin modification associated with gene silencing. AEBP2 enhances PRC2's enzymatic activity and stabilizes its interaction with chromatin, playing a critical role in developmental processes, stem cell differentiation, and maintaining cellular identity. Dysregulation of AEBP2 has been linked to cancers, where its overexpression may promote tumor progression by silencing tumor suppressor genes.
AEBP2 antibodies are widely used in research to study PRC2-dependent gene repression mechanisms, assess protein expression in tissues or cell lines via techniques like Western blotting, immunoprecipitation, or immunofluorescence, and map genomic binding sites through ChIP-seq. These antibodies are essential tools for investigating AEBP2's role in epigenetic diseases, cancer biology, and developmental disorders. Specificity and validation (e.g., using knockout controls) are critical due to potential cross-reactivity with related proteins. Ongoing studies aim to clarify its tissue-specific functions and therapeutic potential as an epigenetic target.